Survival rates have been reported to be higher in colorectal cancer patients treated with cetuximab who develop more severe AfR [1], suggesting that the severity of AfR may be indicative of the EGFR inhibitor's efficacy against cancer. Here, EGFR is linked to colorectal cancer.